Who are Placebo lanreotide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Detectnet, Ga 68 Dotatate, Lutathera, Signifor, Somatuline Depot, Sandostatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-lanreotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo lanreotide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo lanreotide (Placebo lanreotide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin analogue. Area: Endocrinology.

phase 3 Somatostatin analogue Somatostatin receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo lanreotide (Placebo lanreotide) — University Hospital, Limoges. Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo lanreotide TARGET	Placebo lanreotide	University Hospital, Limoges	phase 3	Somatostatin analogue	Somatostatin receptor
Detectnet	copper dotatate Cu-64	Radiomedix	marketed	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
Ga 68 Dotatate	gallium (68Ga) edotreotide	Uihc Pet Imaging	marketed		Somatostatin receptor type 2	2019-01-01
Lutathera	lutetium (177Lu) oxodotreotide	Aaa Usa Inc	marketed		Somatostatin receptor type 2	2018-01-01
Signifor	PASIREOTIDE	Recordati	marketed	Somatostatin Analog [EPC]	Somatostatin receptor type 5	2012-01-01
Somatuline Depot	LANREOTIDE	Ipsen Pharma	marketed	Somatostatin Analog	Somatostatin receptor type 2	2007-01-01
Sandostatin	OCTREOTIDE	Novartis	marketed	Somatostatin Analog	Somatostatin receptor type 2	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-23 — Detectnet · 10383961 · US
2032-08-23 — Detectnet · 10159759 · US
2032-08-23 — Detectnet · 11160888 · US
2038-07-25 — Lutathera · 10596278 · US
2038-07-25 — Lutathera · 10596276 · US

Sponsor landscape (Somatostatin analogue class)

Ludwig-Maximilians - University of Munich · 1 drug in this class
University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo lanreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-lanreotide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing